Trial Profile
A Phase 1, Randomized , Double Blind, Single Ascending Dose Study to Investigate Safety, Tolerability and PK of NP10679 in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2020
Price :
$35
*
At a glance
- Drugs NP 10679 (Primary)
- Indications Epilepsy; Pain; Subarachnoid haemorrhage
- Focus Adverse reactions; First in man
- Sponsors NeurOp
- 18 May 2020 Topline Results published in the NeurOp Media Release.
- 11 Mar 2019 Status changed from recruiting to completed.
- 20 Aug 2018 Planned End Date changed from 21 Aug 2018 to 10 Oct 2018.